A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Part of paid clinical trials in Bakersfield, California.

Sponsor
Apellis Pharmaceuticals, Inc.
Study ID
NCT06161584
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
60 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pegcetacoplan — DRUG
    Administered intravitreally (IVT) in eyes with geographic atrophy (GA)

Study Details

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Key Dates

Start date
Sep 28, 2023
Status verified
May 2026
Primary completion
Jun 30, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: Observation

Primary Outcome Measure

Incidence of ocular AEs in treated eyes overall and according to physician-directed treatment interval based on US prescribing information [ Time Frame: Up to 36 months ]

Locations (34)

FacilityCityStateZIPSite coordinators
California Retina Consultants (01-026)BakersfieldCalifornia93309-
Retina-Vitreous Associates Medical Group (01-020)Beverly HillsCalifornia90211-
Illinois Retina Associates (01-035)FullertonCalifornia92835-
Retinal Consultants Medical Group Inc (01-008)ModestoCalifornia95356-
Retina Consultants San Diego Inc. (01-018)PowayCalifornia92064-
California Retina Consultants (01-027)Santa BarbaraCalifornia93103-
Bay Area Retina Associates (01-005)Walnut CreekCalifornia94598-
Colorado Retina Associates, PLLC (01-011)LakewoodColorado80228-
Retina Specialty Institute (01-019)PensacolaFlorida32503-
South East Retina Center, PC (01-030)AugustaGeorgia30909-
Georgia Retina (01-032)MariettaGeorgia30060-
Illinois Retina Associates (01-037)Oak ParkIllinois60304-
The Retina Care Center (01-023)BaltimoreMaryland21209-
Cumberland Valley Retina Consultants, P.C. (01-002)HagerstownMaryland21740-
Mid Atlantic Retina Specialist (01-029)HagerstownMaryland21740-
Retina Consultants of Minnesota, PLLC (01-025)EdinaMinnesota55435-
Mid Atlantic Retina (01-031)Cherry HillNew Jersey08906-
Mid Atlantic Retina Research (01-014)Cherry HillNew Jersey08034-
OCLI Research Department (01-007)OceansideNew York11572-
Long Island Vitreoretinal Consultants (01-013)WestburyNew York11590-
Western Carolina Retinal Associates, PA (01-009)AshevilleNorth Carolina28803-
Retina Associates of Cleveland, Inc. (01-017)ClevelandOhio44122-
Retina Associates of Cleveland, Inc. (01-022)ClevelandOhio44130-
Retina Associates of Cleveland, Inc. (01-016)YoungstownOhio44505-
Mid Atlantic Retina (01-001)BethlehemPennsylvania18017-
The Retina Care Center (01-034) - Satellite SiteYorkPennsylvania17402-
Black Hills Regional Eye Institute (01-010)Rapid CitySouth Dakota57701-
Tennessee Retina (01-033)NashvilleTennessee37203-
Integrated Clinical Research (01-024)AbileneTexas79606-
Retina Consultants of Texas (01-004)BellaireTexas77401-
Texas Retina Associates (01-028)DallasTexas75231-
Retina Consultants of Texas (01-003)The WoodlandsTexas77384-
The Retina Group of Washington (01-021)FairfaxVirginia22031-
Pacific Northwest Retina (01-036)BellevueWashington98004-

Find similar trials in Bakersfield, CA

By condition
Age-related macular degeneration
By specialty
OphthalmologyRetina
By research site
California Retina Consultants (01-026)· Bakersfield, CARetina-Vitreous Associates Medical Group (01-020)· Beverly Hills, CAIllinois Retina Associates (01-035)· Fullerton, CARetinal Consultants Medical Group Inc (01-008)· Modesto, CARetina Consultants San Diego Inc. (01-018)· Poway, CACalifornia Retina Consultants (01-027)· Santa Barbara, CA

Related Studies